Alpha 2.0
Login Register
» Authors » H-H Parving

H-H Parving

Explore the profile of H-H Parving including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 57
Citations 1195
Followers 0
Related Specialties
Endocrinology
General Medicine
Nephrology
Top 10 Co-Authors
L Tarnow
P Rossing
M Lajer
K J Schjoedt
A Jorsal
F Persson
P Hovind
C D A Stehouwer
D de Zeeuw
K Rossing
Published In
Diabetologia
Diabet Med
Diabetes Obes Metab
Kidney Int
J Intern Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study
Piazza M, Hanssen N, Persson F, Scheijen J, van de Waarenburg M, van Greevenbroek M, et al.
Diabet Med . 2020 Sep; 38(9):e14405. PMID: 32961617
Aim: Angiotensin receptor blockers (ARBs) reduce vascular complications in diabetes independently of blood pressure. Experimental studies suggested that ARBs may restore the detoxifying enzyme glyoxalase 1, thereby lowering dicarbonyls such...
2.
Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients
Holt C, Hoffmann-Petersen I, Hansen T, Parving H, Thiel S, Hovind P, et al.
Immunobiology . 2020 May; 225(3):151939. PMID: 32381273
No abstract available.
3.
Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study
Peeters S, Engelen L, Buijs J, Jorsal A, Parving H, Tarnow L, et al.
Cardiovasc Diabetol . 2017 Apr; 16(1):55. PMID: 28446168
Background: Altered regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in type 1 diabetes. We investigated associations between...
4.
Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes
Ostergaard J, Thiel S, Hoffmann-Petersen I, Hovind P, Parving H, Tarnow L, et al.
Diabetes Metab Res Rev . 2017 Mar; 33(5). PMID: 28303635
Background: Evidence links the lectin pathway of complement activation to diabetic kidney disease. Upon carbohydrate-recognition by pattern-recognition molecules, eg, mannan-binding lectin (MBL), the MBL-associated serine protease (MASP-2) is activated and...
5.
Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia-prone people with Type 1 diabetes
Kristensen P, Tarnow L, Bay C, Norgaard K, Jensen T, Parving H, et al.
Diabet Med . 2017 Jan; 34(5):625-631. PMID: 28099755
Aims: To assess the difference between analogue and human insulin with regard to nocturnal glucose profiles and risk of hypoglycaemia in people with recurrent severe hypoglycaemia. Methods: A total of...
6.
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial
Heerspink H, Ninomiya T, Persson F, Brenner B, Brunel P, Chaturvedi N, et al.
Diabetes Obes Metab . 2015 Oct; 18(2):169-77. PMID: 26511599
Aims: To investigate whether the degree of albuminuria reduction observed in the ALTITUDE trial is associated with renal and cardiovascular protection, and secondly, whether the reduction in albuminuria was too...
7.
Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes
Schievink B, Kropelin T, Mulder S, Parving H, Remuzzi G, Dwyer J, et al.
Diabetes Obes Metab . 2015 Oct; 18(1):64-71. PMID: 26434564
Aims: To develop and validate a model to simulate progression of diabetic kidney disease (DKD) from early onset until end-stage renal disease (ESRD), and to assess the effect of renin-angiotensin...
8.
Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
Theilade S, Claggett B, Hansen T, Skali H, Lewis E, Solomon S, et al.
J Hum Hypertens . 2015 Mar; 30(1):46-52. PMID: 25810068
Pulse pressure (PP) remains an elusive cardiovascular risk factor with inconsistent findings. We clarified the prognostic value in patients with type 2 diabetes, chronic kidney disease (CKD) and anemia in...
9.
ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia
Kristensen P, Diemar S, Bay C, Pedersen-Bjergaard U, Beck-Nielsen H, Christiansen J, et al.
Clin Endocrinol (Oxf) . 2014 Jul; 82(1):155-6. PMID: 25041498
No abstract available.
10.
The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers
Smink P, Miao Y, Eijkemans M, Bakker S, Raz I, Parving H, et al.
Clin Pharmacol Ther . 2013 Sep; 95(2):208-15. PMID: 24067744
Angiotensin receptor blockers (ARBs) have multiple effects that may contribute to their efficacy on renal/cardiovascular outcomes. We developed and validated a risk score that incorporated short-term changes in multiple risk...